The radiotherapy company's novel SADA construct uses self-assembling tetramers to deliver isotopes directly to cancer cells for a highly targeted, less toxic treatment.
- Good Distribution Practice Is Evolving — Here's How
- The 3 Phases of QRM – An Inspector's View
- ADCs Unleashed: Navigating Development Hurdles In Targeted Cancer Therapy
- A Case For Paying Allogeneic Cell Therapy Product Donors
- April 2025 — CDMO Opportunities And Threats Report
- Incorporating AI Tools Into Downstream Process Optimization
- A Road Map For PAT Monitoring And Control
EDITOR'S DESK
-
From BPI West: A Roundtable Discussion On Continuous Manufacturing
Process Development experts share their thoughts on continuous manufacturing at this year's BPI West, touching on its benefits and present barriers to adoption.
Continuous manufacturing was a hot topic of conversation at this year's BPI West. AstraZeneca's Ken Lee, Ph.D., weighs in during an exclusive interview with Bioprocess Online.
Bioprocess Online spoke to an upstream scientist at Bristol Myers Squibb during this year's BPI West. Here's what he had to say.
Bioprocess Online and Cell & Gene spoke with Takeda’s Amy Shaw at BPI West to discuss the industry and her key takeaways from the conference.
Bioprocess Online asked Nathan Lewis, Ph.D., to briefly explain the research he presented at BPI West 2025.
GUEST COLUMNISTS
-
Good Distribution Practice Is Evolving — Here's How
Managing a global supply chain for increasingly complex biologic drugs takes special attention and expertise. Explore the key drivers of a modern logistics management plan.
-
The 3 Phases of QRM – An Inspector's View
Quality resource management has three phases: assessment, control, and review. The experts at GMP Compliance Advisor bring us this breakdown of all of them.
-
ADCs Unleashed: Navigating Development Hurdles In Targeted Cancer Therapy
Despite their potential to revolutionize treatment paradigms, antibody-drug conjugates (ADCs) face challenges that companies must tackle for successful development.
-
A Case For Paying Allogeneic Cell Therapy Product Donors
The debate over whether to pay donors for cell therapy starting materials comes down to four areas of disagreement: altruism, availability, ethics, and safety.
-
April 2025 — CDMO Opportunities And Threats Report
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
Incorporating AI Tools Into Downstream Process Optimization
Data-driven, hybrid modeling complements mechanistic thinking by reducing computational load for faster decision-making when time is a critical consideration.
-
A Road Map For PAT Monitoring And Control
Process analytic technology monitoring and control is rapidly progressing. BioPhorum shares new best practices on how to move from concept through life cycle management and/or regulatory approval of the PAT application.
-
Is Early Automation The Key To Scalable Cell Therapy Manufacturing?
Picking which phase to introduce automation has serious implications, and the calculation is unique for every product. Here are some important considerations.
BIOPROCESSING WHITE PAPERS
-
Novel Cell Lysis Solution: Scaling Up The Harvest Process
To ensure patient safety — as well as a portable process outside of Europe — it’s time to find a novel reagent without harmful, endocrine-disrupting properties.
-
Phase-Appropriate Approaches To Manufacturing And Testing3/14/2025
Accelerate the development of high-quality biopharmaceuticals by implementing phase-appropriate, risk-based manufacturing and testing strategies that ensure timely progression.
-
Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbs4/23/2025
Discover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.
-
Rapid Discovery And Characterization Of Monoclonal Antibodies Against The SARS-CoV-2 Delta Spike Protein4/23/2025
Delve into the intricate workflow employed for the discovery and characterization of monoclonal antibodies (mAbs) targeting the Delta spike protein.
-
The Key To Accelerating RNA-LNP Drug Development12/27/2023
Learn about the drug development hurdles that must be overcome to deliver on the promise of mRNA.
-
Benefits Of PCR-Based mRNA Manufacturing Processes5/17/2024
Learn about a proprietary polymerase chain reaction (PCR) solution that was developed to overcome the challenges associated with pDNA that applies the high accuracy of PCR to mRNA manufacturing.
BIOPROCESSING APP NOTES & CASE STUDIES
- Bypassing The Challenges Of Paper-Based Validation
- The Use Of Injectable Packaging From Early Development To Commercialization
- Development To Large-Scale cGMP Production
- Simplified LV And AAV Clarification With TFDF-Based Intensified Virus Production
- hiPSC Aggregate Expansion In Stirred-Tank Bioreactors
BIOPROCESS ONLINE CONTENT COLLECTIONS

This collection of articles digs into the industry’s growing focus on knowledge management as an indispensable facet of biomanufacturing and pharmaceutical development, exploring how it plays into risk management, quality, vendor relationships, and supply chain resilience.
More Content CollectionsFEATURED PRODUCTS AND SERVICES
ON-DEMAND WEBINARS
- PUPSIT Without The Pain: Practical Solutions For Implementation
- Accelerating Technology Transfer Through Unified Recipe Management
- CLD To Upstream Optimization: Enhancing Biologics Quality, Productivity
- Measuring Thermodynamic Parameters In The Drug Development Process
- Closed System And Custom Solutions For Bioproduction
INDUSTRY NEWS
NEWSLETTER ARCHIVE
- 05.16.25 -- Fluid Management: Suppliers Poised To Meet Demand
- 05.16.25 -- STREAM Edition: How Do Regulations Affect RNA Research?
- 05.16.25 -- The EU Biotech Act Has Been Delayed — Here's What That Means
- 05.15.25 -- Optimize mAb Success: CDC Assays, Glycan Profiling, And ADC QC Strategies
- 05.15.25 -- A Facilities Expert Answers Audience Questions On Construction And Validation